We are analyzing https://link.springer.com/article/10.1007/s00270-018-2069-y.

Title:
Safety and Short-Term Efficacy of Irreversible Electroporation and Allogenic Natural Killer Cell Immunotherapy Combination in the Treatment of Patients with Unresectable Primary Liver Cancer | CardioVascular and Interventional Radiology
Description:
Purpose This study aimed to investigate the safety and short-term efficacy of irreversible electroporation (IRE) combined with allogenic natural killer (NK) cell immunotherapy in the treatment of patients with unresectable primary liver cancer. Materials and Methods Between October 2015 and December 2016, 40 patients were enrolled and randomly allocated to either the IRE group (n = 22) or the IRE–NK group (n = 18). All adverse events experienced by the patients were recorded; the changes in tumor biomarkers [AFP, CA 19-9, circulating tumor cells (CTCs)], lymphocyte number and function, quality of life, clinical response, progression-free survival (PFS) and overall survival (OS) were assessed. Results Patients who received combination therapy exhibited significantly longer median PFS and OS than who just received IRE (PFS 15.1 vs. 10.6 months, P < 0.05, OS 17.9 vs. 23.2 months, P < 0.05). The combination therapy of IRE and NK cell immunotherapy significantly reduced CTCs and increased immune function and Karnofsky performance status. Conclusion Our data suggest a novel, promising combination therapy using IRE and allogenic NK cell immunotherapy. Larger clinical trials are required to confirm these conclusions.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Science
Insurance

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

While profit motivates many websites, others exist to inspire, entertain, or provide valuable resources. Websites have a variety of goals. And this might be one of them. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {🔍}

ire, group, patients, treatment, cells, article, cancer, irenk, pubmed, cell, immunotherapy, google, scholar, tumor, study, ablation, electroporation, irreversible, therapy, significantly, immune, posttreatment, plc, groups, month, liver, blood, efficacy, unresectable, clinical, pfs, cas, function, response, carcinoma, fig, killer, combination, months, hepatocellular, safety, allogenic, combined, size, days, compared, natural, ctcs, number, significant,

Topics {✒️}

provoke graft-versus-host response kir/hla-mismatched nk cells article download pdf contrast-enhanced ct scan ablation modality—clinical implications progression-free survival shows nk cell-based immunotherapy ire–nk therapy procedure cd3 − cd16 + cd56 + cells kir/hla-mismatched donor high-voltage current generator intra-observer reproducibility based advanced hepatocellular carcinoma allogenic natural killer tumor-specific antigen remaining large-volume ablation zones short-term clinical efficacy pfs progression-free survival single-center prospective study full access natural killer cells ctcs 1 month post-treatment ire group post-treatment primary end point nk cell immunotherapy long recurrence-free period il-6 1 month post-treatment groups 1 month post-treatment ire–nk group compared nk-ire group compared systemic anti-tumor efficacy nk cell therapy cell-based immunotherapy privacy choices/manage cookies primary tumor site electronic supplementary material progression-free survival sufficient liver remnant vivo porcine liver minimally invasive therapy including vascular structure global cancer statistics cancer biol ther promising combination therapy fuda cancer hospital irreversible electroporation therapy cell immune response powerful clinical tool renowned killer immunoglobulin percutaneous microwave ablation

Questions {❓}

Irreversible electroporation: ready for prime time?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Safety and Short-Term Efficacy of Irreversible Electroporation and Allogenic Natural Killer Cell Immunotherapy Combination in the Treatment of Patients with Unresectable Primary Liver Cancer
         description:This study aimed to investigate the safety and short-term efficacy of irreversible electroporation (IRE) combined with allogenic natural killer (NK) cell immunotherapy in the treatment of patients with unresectable primary liver cancer. Between October 2015 and December 2016, 40 patients were enrolled and randomly allocated to either the IRE group (n = 22) or the IRE–NK group (n = 18). All adverse events experienced by the patients were recorded; the changes in tumor biomarkers [AFP, CA 19-9, circulating tumor cells (CTCs)], lymphocyte number and function, quality of life, clinical response, progression-free survival (PFS) and overall survival (OS) were assessed. Patients who received combination therapy exhibited significantly longer median PFS and OS than who just received IRE (PFS 15.1 vs. 10.6 months, P < 0.05, OS 17.9 vs. 23.2 months, P < 0.05). The combination therapy of IRE and NK cell immunotherapy significantly reduced CTCs and increased immune function and Karnofsky performance status. Our data suggest a novel, promising combination therapy using IRE and allogenic NK cell immunotherapy. Larger clinical trials are required to confirm these conclusions.
         datePublished:2018-08-27T00:00:00Z
         dateModified:2018-08-27T00:00:00Z
         pageStart:48
         pageEnd:59
         license:http://creativecommons.org/licenses/by/4.0/
         sameAs:https://doi.org/10.1007/s00270-018-2069-y
         keywords:
            Irreversible electroporation
            Natural killer cells
            Primary liver cancer
            Immunotherapy
            Clinical trial
            Imaging / Radiology
            Cardiology
            Nuclear Medicine
            Ultrasound
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00270-018-2069-y/MediaObjects/270_2018_2069_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00270-018-2069-y/MediaObjects/270_2018_2069_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00270-018-2069-y/MediaObjects/270_2018_2069_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00270-018-2069-y/MediaObjects/270_2018_2069_Fig4_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00270-018-2069-y/MediaObjects/270_2018_2069_Fig5_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00270-018-2069-y/MediaObjects/270_2018_2069_Fig6_HTML.png
         isPartOf:
            name:CardioVascular and Interventional Radiology
            issn:
               1432-086X
               0174-1551
            volumeNumber:42
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Yumei Yang
               affiliation:
                     name:The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital
                     address:
                        name:Department of Interventional Therapy, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Zilin Qin
               affiliation:
                     name:Chongqing Health Service Center
                     address:
                        name:Chongqing Health Service Center, Chongqing, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Duanming Du
               url:http://orcid.org/0000-0002-3360-9563
               affiliation:
                     name:The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital
                     address:
                        name:Department of Interventional Therapy, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Yumin Wu
               affiliation:
                     name:The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital
                     address:
                        name:Department of Interventional Therapy, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Shuibo Qiu
               affiliation:
                     name:The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital
                     address:
                        name:Department of Interventional Therapy, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Feng Mu
               affiliation:
                     name:Fuda Cancer Hospital of Jinan University
                     address:
                        name:Department of Oncology, Fuda Cancer Hospital of Jinan University, Guangzhou, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kengcheng Xu
               affiliation:
                     name:Fuda Cancer Institute
                     address:
                        name:Fuda Cancer Institute, Guangzhou, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jibing Chen
               affiliation:
                     name:Fuda Cancer Hospital of Jinan University
                     address:
                        name:Biotherapy Center, Fuda Cancer Hospital of Jinan University, Guangzhou, China
                        type:PostalAddress
                     type:Organization
                     name:Fuda Cancer Institute
                     address:
                        name:Fuda Cancer Institute, Guangzhou, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Safety and Short-Term Efficacy of Irreversible Electroporation and Allogenic Natural Killer Cell Immunotherapy Combination in the Treatment of Patients with Unresectable Primary Liver Cancer
      description:This study aimed to investigate the safety and short-term efficacy of irreversible electroporation (IRE) combined with allogenic natural killer (NK) cell immunotherapy in the treatment of patients with unresectable primary liver cancer. Between October 2015 and December 2016, 40 patients were enrolled and randomly allocated to either the IRE group (n = 22) or the IRE–NK group (n = 18). All adverse events experienced by the patients were recorded; the changes in tumor biomarkers [AFP, CA 19-9, circulating tumor cells (CTCs)], lymphocyte number and function, quality of life, clinical response, progression-free survival (PFS) and overall survival (OS) were assessed. Patients who received combination therapy exhibited significantly longer median PFS and OS than who just received IRE (PFS 15.1 vs. 10.6 months, P < 0.05, OS 17.9 vs. 23.2 months, P < 0.05). The combination therapy of IRE and NK cell immunotherapy significantly reduced CTCs and increased immune function and Karnofsky performance status. Our data suggest a novel, promising combination therapy using IRE and allogenic NK cell immunotherapy. Larger clinical trials are required to confirm these conclusions.
      datePublished:2018-08-27T00:00:00Z
      dateModified:2018-08-27T00:00:00Z
      pageStart:48
      pageEnd:59
      license:http://creativecommons.org/licenses/by/4.0/
      sameAs:https://doi.org/10.1007/s00270-018-2069-y
      keywords:
         Irreversible electroporation
         Natural killer cells
         Primary liver cancer
         Immunotherapy
         Clinical trial
         Imaging / Radiology
         Cardiology
         Nuclear Medicine
         Ultrasound
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00270-018-2069-y/MediaObjects/270_2018_2069_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00270-018-2069-y/MediaObjects/270_2018_2069_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00270-018-2069-y/MediaObjects/270_2018_2069_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00270-018-2069-y/MediaObjects/270_2018_2069_Fig4_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00270-018-2069-y/MediaObjects/270_2018_2069_Fig5_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00270-018-2069-y/MediaObjects/270_2018_2069_Fig6_HTML.png
      isPartOf:
         name:CardioVascular and Interventional Radiology
         issn:
            1432-086X
            0174-1551
         volumeNumber:42
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Yumei Yang
            affiliation:
                  name:The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital
                  address:
                     name:Department of Interventional Therapy, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Zilin Qin
            affiliation:
                  name:Chongqing Health Service Center
                  address:
                     name:Chongqing Health Service Center, Chongqing, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Duanming Du
            url:http://orcid.org/0000-0002-3360-9563
            affiliation:
                  name:The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital
                  address:
                     name:Department of Interventional Therapy, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Yumin Wu
            affiliation:
                  name:The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital
                  address:
                     name:Department of Interventional Therapy, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Shuibo Qiu
            affiliation:
                  name:The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital
                  address:
                     name:Department of Interventional Therapy, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Feng Mu
            affiliation:
                  name:Fuda Cancer Hospital of Jinan University
                  address:
                     name:Department of Oncology, Fuda Cancer Hospital of Jinan University, Guangzhou, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kengcheng Xu
            affiliation:
                  name:Fuda Cancer Institute
                  address:
                     name:Fuda Cancer Institute, Guangzhou, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jibing Chen
            affiliation:
                  name:Fuda Cancer Hospital of Jinan University
                  address:
                     name:Biotherapy Center, Fuda Cancer Hospital of Jinan University, Guangzhou, China
                     type:PostalAddress
                  type:Organization
                  name:Fuda Cancer Institute
                  address:
                     name:Fuda Cancer Institute, Guangzhou, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:CardioVascular and Interventional Radiology
      issn:
         1432-086X
         0174-1551
      volumeNumber:42
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital
      address:
         name:Department of Interventional Therapy, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
         type:PostalAddress
      name:Chongqing Health Service Center
      address:
         name:Chongqing Health Service Center, Chongqing, China
         type:PostalAddress
      name:The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital
      address:
         name:Department of Interventional Therapy, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
         type:PostalAddress
      name:The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital
      address:
         name:Department of Interventional Therapy, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
         type:PostalAddress
      name:The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital
      address:
         name:Department of Interventional Therapy, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
         type:PostalAddress
      name:Fuda Cancer Hospital of Jinan University
      address:
         name:Department of Oncology, Fuda Cancer Hospital of Jinan University, Guangzhou, China
         type:PostalAddress
      name:Fuda Cancer Institute
      address:
         name:Fuda Cancer Institute, Guangzhou, China
         type:PostalAddress
      name:Fuda Cancer Hospital of Jinan University
      address:
         name:Biotherapy Center, Fuda Cancer Hospital of Jinan University, Guangzhou, China
         type:PostalAddress
      name:Fuda Cancer Institute
      address:
         name:Fuda Cancer Institute, Guangzhou, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Yumei Yang
      affiliation:
            name:The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital
            address:
               name:Department of Interventional Therapy, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
               type:PostalAddress
            type:Organization
      name:Zilin Qin
      affiliation:
            name:Chongqing Health Service Center
            address:
               name:Chongqing Health Service Center, Chongqing, China
               type:PostalAddress
            type:Organization
      name:Duanming Du
      url:http://orcid.org/0000-0002-3360-9563
      affiliation:
            name:The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital
            address:
               name:Department of Interventional Therapy, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Yumin Wu
      affiliation:
            name:The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital
            address:
               name:Department of Interventional Therapy, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
               type:PostalAddress
            type:Organization
      name:Shuibo Qiu
      affiliation:
            name:The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital
            address:
               name:Department of Interventional Therapy, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
               type:PostalAddress
            type:Organization
      name:Feng Mu
      affiliation:
            name:Fuda Cancer Hospital of Jinan University
            address:
               name:Department of Oncology, Fuda Cancer Hospital of Jinan University, Guangzhou, China
               type:PostalAddress
            type:Organization
      name:Kengcheng Xu
      affiliation:
            name:Fuda Cancer Institute
            address:
               name:Fuda Cancer Institute, Guangzhou, China
               type:PostalAddress
            type:Organization
      name:Jibing Chen
      affiliation:
            name:Fuda Cancer Hospital of Jinan University
            address:
               name:Biotherapy Center, Fuda Cancer Hospital of Jinan University, Guangzhou, China
               type:PostalAddress
            type:Organization
            name:Fuda Cancer Institute
            address:
               name:Fuda Cancer Institute, Guangzhou, China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Interventional Therapy, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
      name:Chongqing Health Service Center, Chongqing, China
      name:Department of Interventional Therapy, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
      name:Department of Interventional Therapy, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
      name:Department of Interventional Therapy, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
      name:Department of Oncology, Fuda Cancer Hospital of Jinan University, Guangzhou, China
      name:Fuda Cancer Institute, Guangzhou, China
      name:Biotherapy Center, Fuda Cancer Hospital of Jinan University, Guangzhou, China
      name:Fuda Cancer Institute, Guangzhou, China

External Links {🔗}(177)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.2s.

LINK . SPRINGER . COM {}